Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmation
Corresponding Author
Jakub Radocha
Faculty of Medicine in Hradec Králové, 4th Department of Internal Medicine – Hematology, University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
Czech Myeloma Group, Brno, Czech Republic
Correspondence
Jakub Radocha, 4th Department of Internal Medicine - Hematology, University Hospital Hradec Králové, Sokolská 581, 50005 Hradec Králové, Czech Republic.
Email: [email protected]
Search for more papers by this authorTomas Jelinek
Czech Myeloma Group, Brno, Czech Republic
Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
Search for more papers by this authorLudek Pour
Czech Myeloma Group, Brno, Czech Republic
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Usti nad Labem, Czech Republic
Search for more papers by this authorIvan Spicka
Czech Myeloma Group, Brno, Czech Republic
1st Medical Department – Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic
Search for more papers by this authorJiri Minarik
Czech Myeloma Group, Brno, Czech Republic
Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
Search for more papers by this authorTereza Popkova
Czech Myeloma Group, Brno, Czech Republic
Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
Search for more papers by this authorAlexandra Jungova
Czech Myeloma Group, Brno, Czech Republic
Hematology and Oncology Department, Charles University Hospital Pilsen, Pilsen, Czech Republic
Search for more papers by this authorPetr Pavlicek
Czech Myeloma Group, Brno, Czech Republic
Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
Search for more papers by this authorLucie Brozova
Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
Search for more papers by this authorMartin Stork
Czech Myeloma Group, Brno, Czech Republic
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Usti nad Labem, Czech Republic
Search for more papers by this authorFrantisek Sedlak
Czech Myeloma Group, Brno, Czech Republic
1st Medical Department – Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic
Search for more papers by this authorPetra Krhovska
Czech Myeloma Group, Brno, Czech Republic
Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
Search for more papers by this authorVladimir Maisnar
Faculty of Medicine in Hradec Králové, 4th Department of Internal Medicine – Hematology, University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
Czech Myeloma Group, Brno, Czech Republic
Search for more papers by this authorAdriana Heindorfer
Czech Myeloma Group, Brno, Czech Republic
Department of Hematology, Hospital Liberec, Liberec, Czech Republic
Search for more papers by this authorMichal Sykora
Czech Myeloma Group, Brno, Czech Republic
Department of Clinical Hematology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic
Search for more papers by this authorMarek Wrobel
Czech Myeloma Group, Brno, Czech Republic
Department of Hematology, Hospital Novy Jicin, Novy Jicin, Czech Republic
Search for more papers by this authorPeter Mikula
Czech Myeloma Group, Brno, Czech Republic
Department of Clinical Haematology, Hospital in Havirov, Havirov, Czech Republic
Search for more papers by this authorPetr Kessler
Czech Myeloma Group, Brno, Czech Republic
Department of Hematology and Transfusion Medicine, Hospital Pelhrimov, Pelhrimov, Czech Republic
Search for more papers by this authorJana Ullrychova
Czech Myeloma Group, Brno, Czech Republic
Department of Clinical Hematology, Regional Health Corporation, Masaryk Hospital in Usti nad Labem, Usti nad Labem, Czech Republic
Search for more papers by this authorRoman Hajek
Czech Myeloma Group, Brno, Czech Republic
Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
Search for more papers by this authorCorresponding Author
Jakub Radocha
Faculty of Medicine in Hradec Králové, 4th Department of Internal Medicine – Hematology, University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
Czech Myeloma Group, Brno, Czech Republic
Correspondence
Jakub Radocha, 4th Department of Internal Medicine - Hematology, University Hospital Hradec Králové, Sokolská 581, 50005 Hradec Králové, Czech Republic.
Email: [email protected]
Search for more papers by this authorTomas Jelinek
Czech Myeloma Group, Brno, Czech Republic
Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
Search for more papers by this authorLudek Pour
Czech Myeloma Group, Brno, Czech Republic
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Usti nad Labem, Czech Republic
Search for more papers by this authorIvan Spicka
Czech Myeloma Group, Brno, Czech Republic
1st Medical Department – Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic
Search for more papers by this authorJiri Minarik
Czech Myeloma Group, Brno, Czech Republic
Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
Search for more papers by this authorTereza Popkova
Czech Myeloma Group, Brno, Czech Republic
Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
Search for more papers by this authorAlexandra Jungova
Czech Myeloma Group, Brno, Czech Republic
Hematology and Oncology Department, Charles University Hospital Pilsen, Pilsen, Czech Republic
Search for more papers by this authorPetr Pavlicek
Czech Myeloma Group, Brno, Czech Republic
Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
Search for more papers by this authorLucie Brozova
Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
Search for more papers by this authorMartin Stork
Czech Myeloma Group, Brno, Czech Republic
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Usti nad Labem, Czech Republic
Search for more papers by this authorFrantisek Sedlak
Czech Myeloma Group, Brno, Czech Republic
1st Medical Department – Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic
Search for more papers by this authorPetra Krhovska
Czech Myeloma Group, Brno, Czech Republic
Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
Search for more papers by this authorVladimir Maisnar
Faculty of Medicine in Hradec Králové, 4th Department of Internal Medicine – Hematology, University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
Czech Myeloma Group, Brno, Czech Republic
Search for more papers by this authorAdriana Heindorfer
Czech Myeloma Group, Brno, Czech Republic
Department of Hematology, Hospital Liberec, Liberec, Czech Republic
Search for more papers by this authorMichal Sykora
Czech Myeloma Group, Brno, Czech Republic
Department of Clinical Hematology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic
Search for more papers by this authorMarek Wrobel
Czech Myeloma Group, Brno, Czech Republic
Department of Hematology, Hospital Novy Jicin, Novy Jicin, Czech Republic
Search for more papers by this authorPeter Mikula
Czech Myeloma Group, Brno, Czech Republic
Department of Clinical Haematology, Hospital in Havirov, Havirov, Czech Republic
Search for more papers by this authorPetr Kessler
Czech Myeloma Group, Brno, Czech Republic
Department of Hematology and Transfusion Medicine, Hospital Pelhrimov, Pelhrimov, Czech Republic
Search for more papers by this authorJana Ullrychova
Czech Myeloma Group, Brno, Czech Republic
Department of Clinical Hematology, Regional Health Corporation, Masaryk Hospital in Usti nad Labem, Usti nad Labem, Czech Republic
Search for more papers by this authorRoman Hajek
Czech Myeloma Group, Brno, Czech Republic
Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
Search for more papers by this authorJakub Radocha and Tomas Jelinek equally contributed to the work.
Supporting Information
| Filename | Description |
|---|---|
| ijlh13460-sup-0001-FigS1.jpgJPEG image, 125.4 KB | Fig S1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8): e328-e346.
- 2Blade J, Knop S, Cohen AD, Shah JJ, Meyer RM. Interpretation and Application of the International Myeloma Working Group (IMWG) Criteria: Proposal for Uniform Assessment and Reporting in Clinical Trials Based on the First Study Independent Response Adjudication Committee (IRAC) Experience. Blood. 2014; 124(21): 3460.
- 3Lahuerta J-J, Jiménez-Ubieto A, Paiva B, et al. Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. Blood. 2019; 133(25): 2664-2668.
- 4Rajkumar SV, Harousseau J-L, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18): 4691-4695.
- 5 International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121(5): 749-757.
- 6Dejoie T, Corre J, Caillon H, Moreau P, Attal M, Loiseau HA. Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. Leukemia. 2019; 33(2): 313-318.
Citing Literature
